pralsetinib (Gavreto) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA

Back

Chemistry

Mol. Mass

533.61

ALogP

4.2

Rule of 5

No

Rule of 3

No
Details
  • SMILES: CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
  • InChIKey: GBLBJPZSROAGMF-RWYJCYHVSA-N
    InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27+/m0/s1
  • Chirality: Single Stereoisomer
  • Inorganic: No
  • Polymer: No

Sources

CHEMBL4582651   ChEMBL
pralsetinib

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue